[Correspondence] The Study of Letrozole Extension (SOLE) revisited

Several important questions and research considerations arise from the recent report by Marco Colleoni and colleagues.1 The study design of SOLE —4 consecutive years with a 3-month letrozole treatment interruption and a final year of continuous letrozole use (year 5), following completion of 4–6 years of adjuvant anti-oestrogen (tamoxifen or an aromatase inhibitor) therapy, versus 5 years of continuous letrozole—is really a test of pre planned noncompliance rather than an assessment of the therapeutic efficacy of oestrogen-induced apoptosis.

Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: V Craig Jordan Tags: Correspondence Source Type: research